Boosting BCG with recombinant influenza A virus tuberculosis vaccines increases pulmonary T cell responses but not protection against Mycobacterium tuberculosis infection. 2021

Heni Muflihah, and Manuela Flórido, and Leon C W Lin, and Yingju Xia, and James A Triccas, and John Stambas, and Warwick J Britton
Centenary Institute, The University of Sydney, Sydney, New South Wales, Australia.

The current Mycobacterium bovis BCG vaccine provides inconsistent protection against pulmonary infection with Mycobacterium tuberculosis. Immunity induced by subcutaneous immunization with BCG wanes and does not promote early recruitment of T cell to the lungs after M. tuberculosis infection. Delivery of Tuberculosis (TB) vaccines to the lungs may increase and prolong immunity at the primary site of M. tuberculosis infection. Pulmonary immunization with recombinant influenza A viruses (rIAVs) expressing an immune-dominant M. tuberculosis CD4+ T cell epitope (PR8-p25 and X31-p25) stimulates protective immunity against lung TB infection. Here, we investigated the potential use of rIAVs to improve the efficacy of BCG using simultaneous immunization (SIM) and prime-boost strategies. SIM with parenteral BCG and intranasal PR8-p25 resulted in equivalent protection to BCG alone against early, acute and chronic M. tuberculosis infection. Boosting BCG with rIAVs increased the frequency of IFN-γ-secreting specific T cells (p<0.001) and polyfunctional CD4+ T cells (p<0.05) in the lungs compared to the BCG alone, however, this did not result in a significant increase in protection against M. tuberculosis compared to BCG alone. Therefore, sequential pulmonary immunization with these rIAVs after BCG increased M. tuberculosis-specific memory T cell responses in the lung, but not protection against M. tuberculosis infection.

UI MeSH Term Description Entries
D007117 Immunization, Secondary Any immunization following a primary immunization and involving exposure to the same or a closely related antigen. Immunization, Booster,Revaccination,Secondary Immunization,Booster Immunization,Booster Immunizations,Immunizations, Booster,Immunizations, Secondary,Revaccinations,Secondary Immunizations
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D009980 Influenza A virus The type species of the genus ALPHAINFLUENZAVIRUS that causes influenza and other diseases in humans and animals. Antigenic variation occurs frequently between strains, allowing classification into subtypes and variants. Transmission is usually by aerosol (human and most non-aquatic hosts) or waterborne (ducks). Infected birds shed the virus in their saliva, nasal secretions, and feces. Alphainfluenzavirus influenzae,Avian Orthomyxovirus Type A,FLUAV,Fowl Plague Virus,Human Influenza A Virus,Influenza Virus Type A,Influenza Viruses Type A,Myxovirus influenzae-A hominis,Myxovirus influenzae-A suis,Myxovirus pestis galli,Orthomyxovirus Type A,Orthomyxovirus Type A, Avian,Orthomyxovirus Type A, Human,Orthomyxovirus Type A, Porcine,Pestis galli Myxovirus,Fowl Plague Viruses,Influenza A viruses,Myxovirus influenzae A hominis,Myxovirus influenzae A suis,Myxovirus, Pestis galli,Myxoviruses, Pestis galli,Pestis galli Myxoviruses,Plague Virus, Fowl,Virus, Fowl Plague
D005260 Female Females
D000071497 Immunogenicity, Vaccine The capacity of VACCINES to stimulate the ADAPTIVE IMMUNE RESPONSE to produce antibodies and antigen-specific T-CELL responses. It is typically measured in vaccinated individuals in observational studies setting. Antigenicity, Vaccine,Vaccine Antigenicity,Vaccine Immunogenicity
D000091246 Memory T Cells A subset of activated T cells generated in response to primary immune challenge or immunization upon re-challenge (see IMMUNOLOGIC MEMORY). Memory T cells feature many discrete properties indicative of various differentiation such as expression pattern of CCR7 RECEPTORS and can be divided into central memory and effector memory T cells. Central Memory T Cells,Effector Memory T Cells,Memory T Lymphocytes,Tissue Resident Memory T Cells,Virtual Memory T Cells,Lymphocyte, Memory T,Lymphocytes, Memory T,Memory T Cell,Memory T Lymphocyte,T Cell, Memory,T Lymphocyte, Memory,T Lymphocytes, Memory
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic

Related Publications

Heni Muflihah, and Manuela Flórido, and Leon C W Lin, and Yingju Xia, and James A Triccas, and John Stambas, and Warwick J Britton
March 2015, European journal of immunology,
Heni Muflihah, and Manuela Flórido, and Leon C W Lin, and Yingju Xia, and James A Triccas, and John Stambas, and Warwick J Britton
July 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
Heni Muflihah, and Manuela Flórido, and Leon C W Lin, and Yingju Xia, and James A Triccas, and John Stambas, and Warwick J Britton
January 2011, Clinical & developmental immunology,
Heni Muflihah, and Manuela Flórido, and Leon C W Lin, and Yingju Xia, and James A Triccas, and John Stambas, and Warwick J Britton
February 2013, Vaccine,
Heni Muflihah, and Manuela Flórido, and Leon C W Lin, and Yingju Xia, and James A Triccas, and John Stambas, and Warwick J Britton
February 2016, Immunologic research,
Heni Muflihah, and Manuela Flórido, and Leon C W Lin, and Yingju Xia, and James A Triccas, and John Stambas, and Warwick J Britton
February 2006, Lancet (London, England),
Heni Muflihah, and Manuela Flórido, and Leon C W Lin, and Yingju Xia, and James A Triccas, and John Stambas, and Warwick J Britton
February 2006, Lancet (London, England),
Heni Muflihah, and Manuela Flórido, and Leon C W Lin, and Yingju Xia, and James A Triccas, and John Stambas, and Warwick J Britton
February 2006, Lancet (London, England),
Heni Muflihah, and Manuela Flórido, and Leon C W Lin, and Yingju Xia, and James A Triccas, and John Stambas, and Warwick J Britton
April 2017, Human vaccines & immunotherapeutics,
Heni Muflihah, and Manuela Flórido, and Leon C W Lin, and Yingju Xia, and James A Triccas, and John Stambas, and Warwick J Britton
November 2009, Microbes and infection,
Copied contents to your clipboard!